Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Finished Goods (2025)

BridgeBio Pharma (BBIO) has disclosed Finished Goods for 1 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Finished Goods changed N/A to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.5 million for FY2025, N/A changed from the prior year.
  • Finished Goods hit $6.5 million in Q4 2025 for BridgeBio Pharma, up from $5.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $6.5 million in Q4 2025 to a low of $2.6 million in Q1 2025.